Vesicular acetylcholine transporter Antibody

Validation and Specificity

VAChT antibodies undergo rigorous validation to ensure specificity:

• Peptide Blocking: Staining is abolished by pre-adsorption with the immunizing peptide .

• RNA Interference (RNAi): Knockdown of VAChT in Drosophila reduces antibody signal, confirming target specificity .

• Co-localization Studies: VAChT antibodies colocalize with synaptic vesicle markers (e.g., CSP2) in neuronal terminals .

Validation Data

Research Applications

VAChT antibodies are pivotal in studying cholinergic systems:

• Neurological Disorders: PET imaging probes using VAChT inhibitors aid in diagnosing Alzheimer’s disease .

• Developmental Biology: In Drosophila, VAChT regulates synaptic vesicle ACh content; polyglutamine tract modifications alter neurotransmission efficiency .

• Congenital Myasthenic Syndromes (CMS): VAChT mutations (e.g., Gly360Arg) cause severe hypotonia and respiratory failure due to protein instability .

Key Findings Using VAChT Antibodies

Limitations and Future Directions

• Cross-Reactivity: Some antibodies may weakly label non-cholinergic neurons due to epitope sharing .

• Quantitative Challenges: VAChT expression levels vary across tissues, necessitating standardized protocols .